Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Bone marrow blast elimination by the fifth day of 7 + 3 induction is the strongest predictor of potential cure in patients with acute myeloid leukemia younger than 61 years of age: A long-term follow-up of a multi-center prospective study.

Ofran Y, Hayun M, Leiba R, Zuckerman T, Horowitz N, Hoffman R, Ringelstein S, Lavi N, Frisch A, Henig I, Gatt ME, Hellmann I, Arad A, Bulvik S, Ram R, Gino-Moor S, Saban R, Tvito A, Rowe JM, Ganzel C.

Am J Hematol. 2020 Jan;95(1):E3-E5. doi: 10.1002/ajh.25651. Epub 2019 Oct 17. No abstract available.

PMID:
31591736
2.

Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia.

Ofran Y, Ringelstein-Harlev S, Slouzkey I, Zuckerman T, Yehudai-Ofir D, Henig I, Beyar-Katz O, Hayun M, Frisch A.

Leukemia. 2020 Jan;34(1):293-295. doi: 10.1038/s41375-019-0548-z. Epub 2019 Aug 21. No abstract available.

PMID:
31435023
3.

Proinflammatory Macrophages Promote Multiple Myeloma Resistance to Bortezomib Therapy.

Beyar-Katz O, Magidey K, Reiner-Benaim A, Barak N, Avivi I, Cohen Y, Timaner M, Avraham S, Hayun M, Lavi N, Bersudsky M, Voronov E, Apte RN, Shaked Y.

Mol Cancer Res. 2019 Nov;17(11):2331-2340. doi: 10.1158/1541-7786.MCR-19-0487. Epub 2019 Aug 13.

PMID:
31409628
4.

Grb2 regulates the proliferation of hematopoietic stem and progenitors cells.

Frelin C, Ofran Y, Ruston J, Hayun M, Derdikman Y, Khier Y, Rozales K, Brenner B, Iscove N, Pawson T, Louria-Hayon I.

Biochim Biophys Acta Mol Cell Res. 2017 Dec;1864(12):2449-2459. doi: 10.1016/j.bbamcr.2017.09.018. Epub 2017 Sep 28.

5.

Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the "3 + 7" induction regimen for acute myeloid leukemia.

Ofran Y, Leiba R, Ganzel C, Saban R, Gatt M, Ram R, Arad A, Bulvik S, Hellmann I, Gino-Moor S, Zuckerman T, Hoffman R, Horowitz N, Lavi N, Ringelstein S, Henig I, Hayun M, Rowe JM.

Am J Hematol. 2015 Dec;90(12):1159-64. doi: 10.1002/ajh.24207. Epub 2015 Nov 17.

6.

Multiple signal transduction pathways are involved in G2/M growth arrest and apoptosis induced by the immunomodulator AS101 in multiple myeloma.

Naor Y, Hayun M, Sredni B, Don J.

Leuk Lymphoma. 2013 Jan;54(1):160-6. doi: 10.3109/10428194.2012.704032. Epub 2012 Sep 5.

PMID:
22712839
7.

Induction therapy in a multiple myeloma mouse model using a combination of AS101 and melphalan, and the activity of AS101 in a tumor microenvironment model.

Hayun M, Saida H, Albeck M, Peled A, Haran-Ghera N, Sredni B.

Exp Hematol. 2009 May;37(5):593-603. doi: 10.1016/j.exphem.2009.01.006.

PMID:
19375650
8.

Synergistic effect of AS101 and Bryostatin-1 on myeloid leukemia cell differentiation in vitro and in an animal model.

Hayun M, Okun E, Hayun R, Gafter U, Albeck M, Longo DL, Sredni B.

Leukemia. 2007 Jul;21(7):1504-13. Epub 2007 May 17.

PMID:
17508000
9.

Characterization and activity of sonochemically-prepared BSA microspheres containing Taxol--an anticancer drug.

Grinberg O, Hayun M, Sredni B, Gedanken A.

Ultrason Sonochem. 2007 Jul;14(5):661-6. Epub 2007 Jan 8.

PMID:
17208504
10.

The immunomodulator AS101 induces growth arrest and apoptosis in multiple myeloma: association with the Akt/survivin pathway.

Hayun M, Naor Y, Weil M, Albeck M, Peled A, Don J, Haran-Ghera N, Sredni B.

Biochem Pharmacol. 2006 Nov 30;72(11):1423-31. Epub 2006 Aug 4.

PMID:
16889755

Supplemental Content

Support Center